Companies / Crescent Biopharma, Inc.
Crescent Biopharma, Inc.
Nasdaq: CBIOCIK 1253689WALTHAM, MA
Financials · FY2025
Ownership
37.1M shares outstanding · as of Jul 27, 2026
Ownership
| 10%+ / strategic | 14.25% | 5,293,514 |
| Institutions | 59.97% | 22,274,099 |
| Public float | 25.78% | 9,576,327 |
% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.
Insiders 15
View all →| Insider | % of shares | Shares |
|---|---|---|
Balcom AlexandraDirector | — | — |
Bispham Barbara HarlinFormerSee Remarks | — | — |
Brumm Joshua TCEOChief Executive Officer · Director | — | — |
Fairmount Funds Management LLCFormerDirector · 10% owner | — | — |
Fairmount Healthcare Fund II L.P.FormerDirector · 10% owner | — | — |
Harwin Peter EvanDirector · 10% owner | — | — |
Im Ellie EunkyungChief Medical Officer | — | — |
Kiselak TomasFormerDirector · 10% owner | — | — |
Lubner David CharlesDirector | — | — |
Lynch RyanFormerSee Remarks | — | — |
Institutional holders 62
View all →| Holder | Value | % of shares |
|---|---|---|
| $50.49M | 7.40% | |
| $49.02M | 11.13% | |
| $32.59M | 7.40% | |
| $27.74M | 4.07% | |
| $25.30M | 5.74% | |
| $22.89M | 3.42% | |
| $21.31M | 3.12% | |
| $19.90M | 4.52% | |
| $17.79M | 4.04% | |
| $13.97M | 3.17% |
Activity
InsidersInstitutions
What insiders are doing in this stock (Form 4).| Date | Actor | Action | Security | Value | Shares Δ | Position after | Impact |
|---|---|---|---|---|---|---|---|
| Jun 22, 2026 | Brumm Joshua T CEO | Sell | Ordinary Shares | $761.1K | -42K -13.08% | 281,212 0.76% of shares | medium |
| Jun 22, 2026 | McNeill Jonathan Executive | Sell | Ordinary Shares | $369.7K | -21K -12.87% | 139,158 0.37% of shares | medium |
| Jun 22, 2026 | Pinkas Jan Executive | Sell | Ordinary Shares | $23.2K | -1K -5.47% | 22,239 0.06% of shares | low |
| Jun 22, 2026 | Im Ellie Eunkyung Executive | Sell | Ordinary Shares | $21.9K | -1K -5.23% | 22,069 0.06% of shares | low |
| Jun 22, 2026 | Bispham Barbara Harlin Executive | Sell | Ordinary Shares | $21.9K | -1K -5.93% | 19,330 0.05% of shares | low |
| Jun 22, 2026 | Scalzo Richard William Executive | Sell | Ordinary Shares | $20.0K | -1K -5.19% | 20,298 0.05% of shares | low |
| Jun 22, 2026 | Lynch Ryan Executive | Sell | Ordinary Shares | $8.4K | -465 -3.24% | 13,871 0.04% of shares | low |
| Jun 2, 2026 | Violin Jonathan Director | Grant | Stock Option (Right to Buy) | — | +11K | 11,050 0.03% of shares | low |
5%+ ownership events
Schedule 13D / 13G
| Filer | Stance | % of class |
|---|---|---|
| Fmr LLC | Passive13G/A | — |
| Venrock Healthcare Capital Partners III, L.P. | Passive13G/A | — |
| Vestal Point Capital, LP | Passive13G | — |
| Balyasny Asset Management L.P. | Passive13G | — |
| Tang Capital Management, LLC | Passive13G/A | — |
Securities
via CUSIP / OpenFIGI
| Symbol | Type | CUSIP |
|---|---|---|
| CBIO | — | 38000Q201 |
| CBIO | — | G2545C104 |